4 results about "Human cartilage" patented technology

The present invention provides a recombinant human type II collagen fragment, the amino acid sequence is shown in SEQ ID NO.2, and the coding gene sequence is shown in SEQ ID NO.1. The present invention also provides an expression vector and Pichia pastoris engineering bacteria comprising the above-mentioned recombinant human type II collagen fragment coding gene. At the same time, the present invention also provides a preparation and application of the above-mentioned recombinant human type II collagen fragment. The recombinant human type II collagen fragment of the present invention not only has a significant effect on promoting the proliferation and migration of human chondrocytes, but also shows excellent effects of promoting cell migration and promoting adhesion in human immortalized epidermal cells and mouse embryonic fibroblasts, and can be widely used in artificial bones, artificial cartilage, artificial corneas, vitreous bodies, wound repair materials, supporting biomaterials, medical cosmetic surgery, cosmetics and other fields.

It is an object of the present invention a method to obtain a cartilage cell population enriched in cartilage progenitor cells (CPCs), said method comprising culturing said cells in culture at a density between 10 and 500 cells / cm2. In a further aspect, it is here claimed a population of cartilage cells enriched in CPCs obtainable by means of said method, and their use in the treatment of chondral lesions or joint degeneration.

This invention relates to a method for constructing a humanized pig model of type II collagen and its application, belonging to the field of gene modification technology. The invention first provides a CRISPR-Cas9 system for targeted editing of the porcine type II collagen α1 gene. Using CRISPR / Cas9-mediated homologous recombination, the porcine COL2A1 gene is orally replaced with the human COL2A1 gene. Then, using somatic cell cloning technology, a humanized pig model of type II collagen is constructed, allowing the pig to produce cartilage tissue more similar to that of humans, reducing post-transplant immune rejection. This is expected to fundamentally solve the problem of human cartilage tissue shortage and has significant implications for the treatment of articular cartilage damage, providing a better and more suitable transplant material for the treatment of articular cartilage damage.

The invention relates to an optimized formula containing ossein and casein phosphopeptides by combining glucosamine for increasing bone mineral density with traditional Chinese medicines of rhizoma drynariae and radix morindae officinalis. The treatment situation of bone joints is that some medicines for relieving symptoms are used for treating patients, the symptoms are not affected by basic lesions of osteoarthritis, and the medicines are large in side effect and not suitable for being taken for a long time. According to a modern nutriology theory and a brand-new reasonable and scientific formula, the active ingredients can stimulate chondrocytes to synthesize a large amount of human cartilage matrixes, and can stimulate human bodies to synthesize glucosamine and collagen, so that the consumption of lost proteoglycan and collagen organic matters in bone matrixes is made up. The traditional Chinese medicine composition can effectively improve bone mineral density, resist osteoporosis, eliminate breathing and waist and back pain symptoms caused by osteoporosis, inhibit activity of cartilage destroying enzyme and continuously repair abraded articular cartilage or articular cartilage destroyed by inflammatory substances, so that normal physiological functions of joint parts are recovered, and the traditional Chinese medicine composition can be taken for a long time.